Abiomed (Danvers, Massachusetts) named Frank Menzler general manager for Abiomed BV, the company's European division. Menzler most recently was marketing manager for cardiac surgery for Guidant Europe and was a co-founder of Impella Cardiotechnik AG, a developer of minimally invasive blood pumps. Abiomed is a maker of medical products designed to assist or replace the pumping function of the failing heart.
Robin Weiner has joined Biosite (San Diego) as vice president, regulatory and government affairs. She most recently served as vice president, clinical and regulatory affairs at Quidel, prior to which she was with Scripps Clinic and Research Foundation, the University of California, San Diego and the Veterans Affairs Medical Center. Biosite is a developer of protein-based diagnostics for toxicology screening and diagnosis of infectious and cardiovascular disease.
Craig Smith, MD, will retire as chairman, president and CEO of Guilford Pharmaceuticals (Baltimore). Smith, a co-founder of Guilford, will remain in those positions until the company's next annual meeting, unless a successor is identified earlier. After his retirement, Smith will continue as a director and will serve as a consultant to the company for at least one year. Guilford Pharmaceuticals markets the Gliadel Wafer for the treatment of brain cancer and Aggrastat Injection, a glycoprotein GP IIb/IIIa receptor antagonist, for treatment of acute coronary syndrome.
Marc Flores has been named president, CEO and a member of the board of directors of MedicalCV (Minneapolis). Lawrence Horsch, who had been serving as acting CEO, will remain chairman of the board. Flores most recently served as vice president of sales and marketing at Coalescent Surgical. MedicalCV makes the Omnicarbon 3000 and 4000 heart valves, and said its near-term plans include the development of products targeting treatment of atrial fibrillation. Adam Berman has been named vice president, research and development. He most recently was a regional sales manager for cardiac surgery-focused Coalescent Surgical. Medical CV is focused on developing products for improved patient outcomes by early treatment of cardiovascular disorders.
Carole Marcot has joined SynCardia Systems (Tucson, Arizona) as vice president of quality and regulatory affairs. Marcot most recently served as vice president, regulatory affairs and quality systems at Ventana Medical Systems. SynCardia, a developer of biomechanical heart replacement and assist devices, is seeking FDA approval of the CardioWest Total Artificial Heart.